Skip to content
AnalystLens

BOSTON SCIENTIFIC CORP 8-K Report, Shareholder Vote Results (May 6, 2025)

Reports
Shareholder Matters
Filing Date
Filed May 6, 2025
Period End
May 1, 2025
Security
BSX
In the record · 2016–202610-K1310-Q328-K181

BSX filed 13 annual reports (10-K), 32 quarterly reports (10-Q) and 181 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Nov ’18Nov ’18
  2. Restructuring8-K · Dec ’20Dec ’20
  3. Leadership change8-K · Jan ’23Jan ’23
  4. Leadership change8-K · Oct ’26Oct ’26

Summary

Summary of the 8-K filed May 6, 2025. Cited figures are marked; the original filing is the authoritative source.

Boston Scientific Corporation (BSX) filed an 8-K report detailing the outcomes of its 2025 Annual Meeting of Stockholders, held on May 1, 2025.

The meeting confirmed strong shareholder support for the company's leadership and governance. All ten director nominees were overwhelmingly elected for a one-year term, indicating continued confidence in the current board's direction and oversight.

Furthermore, the stockholders provided advisory approval for the compensation of the Named Executive Officers and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year 2025. A stockholder proposal supporting a simple majority vote was also approved on an advisory basis, suggesting a shareholder preference for a more straightforward voting mechanism.

Key Highlights

  1. All 10 director nominees were re-elected to the Board of Directors with substantial majority support.
  2. Shareholders provided advisory approval for the compensation of the Company’s Named Executive Officers.
  3. Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year 2025.
  4. A stockholder proposal titled 'Support Simple Majority Vote' was approved on an advisory basis.
  5. The Annual Meeting was held virtually via live webcast.
  6. There were significant 'Broker Non-Votes' reported across most resolutions, particularly for director elections and executive compensation.

Frequently Asked Questions

  1. What were the main outcomes of the Boston Scientific 2025 Annual Meeting of Stockholders?

    The primary outcomes include the re-election of all ten director nominees, advisory approval of executive compensation, ratification of Ernst & Young LLP as the independent auditor, and advisory approval of a 'Support Simple Majority Vote' stockholder proposal.

  2. How did shareholders vote on the director nominees?

    All ten director nominees received overwhelming support, with 'For' votes significantly outnumbering 'Against' and 'Abstain' votes. This indicates strong shareholder confidence in the current Board of Directors.

  3. What is the significance of the advisory vote on executive compensation?

    The advisory vote on executive compensation, often referred to as 'Say-on-Pay', allows shareholders to express their views on the compensation packages awarded to the company's top executives. The approval indicates general shareholder satisfaction with the compensation practices.

  4. Why is the ratification of the independent auditor important?

    Ratifying the independent auditor, in this case Ernst & Young LLP, confirms shareholder confidence in the firm's ability to provide an objective and independent audit of the company's financial statements. This is crucial for maintaining financial transparency and investor trust.